

Contents

Contributors	xv
Abbreviations and Conventions	xvii
1 Regulation of the Eukaryotic Cell Cycle	
<i>R.F. Brooks</i>	1
Introduction	1
Mitosis-Promoting Factor	2
The <i>cdc2</i> Gene	3
Histone H1 Kinase	4
Activation of Mitosis-Promoting Factor	5
Cyclins	5
Phosphorylation and Dephosphorylation of p34 ^{cdc2}	6
<i>cdc25</i> and the Timing of MPF Activation	10
Dependence of Mitosis on DNA Synthesis	11
The <i>wee1</i> and <i>nim1</i> Genes	11
The <i>suc1</i> Gene	12
Calcium	12
Why Two Classes of Cyclin?	13
Exit from Mitosis	15
Cyclin Degradation	15
Regulation of Cyclin Destruction by the Mitotic Spindle ..	15
Cytostatic Factor and <i>c-mos</i> Proto-oncogene	16
Cell Cycle Initiation	16
Role of <i>cdc2</i>	16
G ₁ Cyclins	17
Conclusion	19
2 Growth Factors, Oncogenes and Tumour Suppressor Genes	
<i>D.P. Hollywood and N.R. Lemoine</i>	27
Introduction	27
Growth Factors and Growth Factor Receptors	29
Cytoplasmic Signal Transduction Pathways	31
Immediate Early Genes	33
The <i>fos</i> and <i>jun</i> Genes	34
The <i>myc</i> Genes	35

Other Immediate Early Genes	36
Steroid Receptors	37
Tumour Suppressor Genes	38
The p53 Gene	38
Retinoblastoma Protein	40
Conclusion	41
3 The Kinetic Organisation of Tissues	
<i>B. Ansari and P.A. Hall</i>	45
Introduction	45
The General Organisation of Tissues	46
Evidence for the Existence of Stem Cells	46
Regulation of Stem Cells and the Lineages Derived from Them	48
Regulation by Position	48
Regulation by Intercellular Communication	50
Negative Regulators of Cell Proliferation	51
Control of Cell Number and Heterochrony	52
Regulation by Growth Arrest	53
Regulation by Cell Death	54
Do Stem Cells Exist in Conditional Renewal Tissues?	55
Cellular Heterogeneity in Tumours	57
Conclusion	58
4 Basic Methods for Assessing Cellular Proliferation	
<i>R. Dover</i>	63
Introduction	63
The Cell Cycle	63
Growth Fraction	64
Cell Loss	65
Growth Curves	66
Age Distribution	66
State Measurements	68
Thymidine Incorporation	68
Non-Autoradiographic Method of Detecting Incorporated Thymidine	70
Mitotic and Labelling Indices	70
The Fraction Labelled Mitoses Method	71
The Continuous Labelling Method	73
Thymidine Labelling – Clinical Applications	74
Flow Cytometry	75
Summary	76
Rate Measurements	76
The Rate of Entry into S Phase	77
The Rate of Entry into Mitosis	78
Summary	79
Conclusion	79

5 Mitosis Counting	
<i>C.M. Quinn and N.A. Wright</i>	83
Introduction	83
Mitosis Counting – Methods	83
Mitotic Count	83
Mitotic Index	84
Mitotic Rate	84
Mitosis Counting – Applications	84
Uterine Smooth Muscle Tumours	84
Gastrointestinal Smooth Muscle (Stromal) Tumours	86
Endometrial Stromal Sarcomas	86
Placental Site Trophoblastic Tumour	87
Ovarian Neoplasms	87
Lymphomas	88
Other Applications	88
Mitosis Counting – Advantages	88
Mitosis Counting – Limitations	89
Tumour Heterogeneity	89
Delay in Fixation	89
Inter-Observer Variation	89
Cell Size Variation	90
Variation in the Area of High-Power Fields	90
Conclusion	91
6 Flow Cytometry	
<i>R.S. Camplejohn and J.C. Macartney</i>	95
Introduction	95
Development and Properties of Flow Cytometers	95
General Advantages and Disadvantages of Flow Cytometry	96
DNA Flow Cytometry	96
Introduction	96
Methodology	98
Clinical Value	102
Multiparameter Flow Cytometry	106
Conclusion	108
7 Measurement of Cell Proliferation Using Bromodeoxyuridine	
<i>G.D. Wilson and N.J. McNally</i>	113
Introduction	113
The Parameters of Tumour Cell Proliferation	114
Flow Cytometric Methods	115
Tissue Preparation and Staining	115
Data Acquisition	116
Data Analysis	117
The Relative Movement Method	117
Modifications of the Single Relative Movement Calculation	123

Comparisons of Analytical Methods in the Context of Solid Tumours	124
Intra- and Inter-Tumour Heterogeneity	126
Immunohistochemical Localisation of BUdR	129
Staining Procedure	129
Clinical Correlations	134
Conclusion	136
8 The Application of Immunohistochemistry in Assessment of Cellular Proliferation	
<i>C.C.-W. Yu, A.L. Woods and D.A. Levison</i>	141
Introduction	141
Cell Cycle Associated Antigens	141
Ki-67 Antigen	142
Proliferating Cell Nuclear Antigen	143
DNA Polymerase δ and α	148
p125/6.5 Antigen	149
K 112 Antigen	149
Transferrin Receptor	150
Mitosis-Associated Changes	150
Bromodeoxyuridine	150
Markers of Quiescent and non-Proliferating Cells	150
Markers of Transition from the Quiescent to the Proliferative State	152
Quantification and Interpretation of Results	152
Conclusion	153
9 Nucleolar Organiser Regions	
<i>J.C.E. Underwood</i>	161
Introduction	161
Nucleolar Organiser Regions and Nucleoli	161
Argyrophilic NORs	162
Demonstration of NORs	163
AgNOR Staining Techniques	164
Enumeration of AgNORs	165
Tissue Sampling	165
Section Thickness	165
NOR Aggregation and Segregation	165
NOR Numbers and Ploidy	166
Transcriptional Activity	166
Assessment of AgNORs in Interphase Nuclei	167
Sample Size	167
Effect of AgNOR Superimposition and Aggregation	167
AgNOR Number per Nucleus	168
AgNOR Area	168
AgNOR Assessment by Image Analysis	169
Significance of High AgNOR Counts	169
Proliferation or Ploidy?	170
Correlation with Other Indices of Proliferation	170

Non-Hodgkin's Lymphoma	171
Breast Carcinoma	172
Lung Carcinomas	172
Applications in Histopathology	172
Conclusion	173
10 Clinical Aspects of Assessing Cell Proliferation	
<i>S.M. O'Reilly and M.A. Richards</i>	177
Introduction	177
Methods Used to Assess Cell Proliferation	177
Clinical Applications	178
Diagnosis	178
Prognosis	180
Predicting Response to Treatment	185
Conclusion	186
11 Cell Proliferation and the Principles of Cancer	
Chemotherapy	
<i>W.M. Gregory</i>	193
Evolution of the Principles	193
The Principles in Practice	194
Application to Particular Neoplasms	194
Application in Choice of Treatment for Individuals	196
New Approaches to Estimating Resistance and Growth	
Rates	196
Mathematical Model Description and Development	197
Model Applications	199
Conclusion	202
Subject Index	207